Off-label use of biologic agents in the treatment of dermatosis, Part 1: Infliximab and adalimumab;Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera Parte: Infliximab y adalimumab

Actas Dermo-Sifiliograficas

Volumn 98, Issue 10, 2007, Pages 657-678

  Díaz Ley, Blanca ^a   Guhl, G ^a   Fernandez Herrera J ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Adalimumab; Dermatosis; Infliximab; Off label

Indexed keywords

ADALIMUMAB; CHLORAMBUCIL; COLCHICINE; CYCLOSPORIN; DERMATOLOGICAL AGENT; INFLIXIMAB; METHYLPREDNISOLONE; PENICILLIN G; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACNE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; BEHCET DISEASE; CHURG STRAUSS SYNDROME; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG USE; GIANT CELL ARTERITIS; GRANULOMA ANNULARE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NECROBIOSIS LIPOIDICA; POLYARTERITIS NODOSA; PSORIASIS; REVIEW; SAPHO SYNDROME; SARCOIDOSIS; SCLERODERMA; SJOEGREN SYNDROME; SKIN DISEASE; SKIN INFLAMMATION; SUPPURATIVE HIDRADENITIS; TOXIC EPIDERMAL NECROLYSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HUMANS; PRESCRIPTIONS, DRUG; SKIN DISEASES;

EID: 37749029379     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S1578-2190(07)70539-5     Document Type: Review

References (283)

1. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56:55-79.
2. Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg. 2006;25:226-40.
3. Jacobi A, Manger B, Schuler G, Hertl M. [Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders]. J Dtsch Dermatol Ges. 2003;1:259-72.
4. Trent JT, Kerdel FA. Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs. 2005;17:97-107.
5. Williams JD, Griffiths CE. Cytokine blocking agents in dermatology. Clin Exp Dermatol. 2002;27:585-90.
6. Scheinfeld N. The medical uses and side effects of etanercept with a focus on cutaneous disease. J Drugs Dermatol. 2004;3:653-9.
7. Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg. 2005;9:296-302.
8. Arend WP. The mode of action of cytokine inhibitors. J Rheumatol. 2002;65:16-21.
9. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241-8.
10. http://www.emea.europa.eu/pdfs/human/opinion/23072006en.pdf
11. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31:1912-7.
12. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-24.
13. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. [Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity-secondary publication]. Ugeskr Laeger. 2007;169:420-3.
14. Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Management of ulcerative colitis and Crohn's disease. Acta Clin Belg. 2004;59:304-14.
15. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-8.
16. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-9.
17. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol. 2007;34:510-5.
18. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with antitumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-9.
19. Vermeire S, Noman M, van Assche G, Baert F, D'Haens G, Rutgeerts PJ. The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in crohn's disease. Gut. 2007. En prensa.
20. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-24.
21. Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol. 2004;16:393-8.
22. Kindler V, Sappino AP. The beneficial effects of localized tumor necrosis factor production in BCG infection. Behring Inst Mitt. 1991;88:120-4.
23. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-8.
24. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39:303-6.
25. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-9.
26. Thomas CW Jr., Weinshenker BG, Sandborn WJ. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis. 2004;10:28-31.
27. Tran TH, Milea D, Cassoux N, Bodaghi B, Bourgeois P, LeHoang P. [Optic neuritis associated with infliximab]. J Fr Ophtalmol. 2005;28:201-4.
28. Devergne O, Emilie D, Peuchmaur M, Crevon MC, D'Agay MF, Galanaud P. Production of cytokines in sarcoid lymph nodes: preferential expression of interleukin-1 beta and interferon-gamma genes. Hum Pathol. 1992;23:317-23.
29. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56:731-40.
30. Senaldi G, Yin S, Shaklee CL, Piguet PF, Mak TW, Ulich TR. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol. 1996;157:5022-6.
31. Hino T, Nakamura H, Shibata Y, Abe S, Kato S, Tomoike H. Elevated levels of type II soluble tumor necrosis factor receptors in the bronchoalveolar lavage fluids of patients with sarcoidosis. Lung. 1997;175:187-93.
32. Muller-Quernheim J, Pfeifer S, Mannel D, Strausz J, Ferlinz R. Lung-restricted activation of the alveolar macrophage/ monocyte system in pulmonary sarcoidosis. Am Rev Respir Dis. 1992;145:187-92.
33. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Muller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med. 1997;156:1586-92.
34. Antoniu SA. Infliximab for the therapy of chronic sarcoidosis, Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Expert Opin Investig Drugs. 2007;16:753-6.
35. Almodóvar R, Izquierdo M, Zarco P, Javier Quiros F, Mazzucchelli R, Steen B. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2007;25:99-101.
36. Uthman I, Touma Z, Khoury M. Cardiac sarcoidosis responding to monotherapy with infliximab. Clin Rheumatol. 2007. En prensa.
37. Denys BG, Bogaerts Y, Coenegrachts KL, De Vriese AS. Steroid-resistant sarcoidosis: is antagonism of TNF-alpha the answer? Clin Sci (Lond). 2007;112:281-9.
38. Salama B, Gicquel JJ, Lenoble P, Dighiero PL. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol. 2006;41:766-8.
39. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum. 2003;48:3542-3.
40. Sollberger M, Fluri F, Baumann T, Sonnet S, Tamm M, Steck AJ, et al. Successful treatment of steroid-refractory neurosarcoidosis with infliximab. J Neurol. 2004;251:760-1.
41. Pettersen JA, Zochodne DW, Bell RB, Martin L, Hill MD. Refractory neurosarcoidosis responding to infliximab. Neurology. 2002;59:1660-1.
42. Menon Y, Cucurull E, Reisin E, Espinoza LR. Interferon-alpha-associated sarcoidosis responsive to infliximab therapy. Am J Med Sci. 2004;328:173-5.
43. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med. 2004;117:277-9.
44. Badgwell C, Rosen T. Cutaneous sarcoidosis therapy updated. J Am Acad Dermatol. 2007;56:69-83.
45. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:70-4.
46. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005;141:910-1.
47. Mallbris L, Ljungberg A, Hedblad MA, Larsson P, Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol. 2003;48:290-3.
48. Meyerle JH, Shorr A. The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol. 2003;2:413-4.
49. Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol. 2004;150:146-9.
50. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63:318-20.
51. Roberts SD, Wilkes DS, Burgett RA, Knox KS. Refractory sarcoidosis responding to infliximab. Chest. 2003;124:2028-31.
52. Sweiss NJ, Welsch MJ, Curran JJ, Ellman MH. Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosis. Arthritis Rheum. 2005;53:788-91.
53. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med. 2001;135:27-31.
54. Serio RN. Infliximab treatment of sarcoidosis. Ann Pharmacother. 2003;37:577-81.
55. Cruz BA, Reis DD, Araujo CA. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int. 2007. En prensa.
56. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med. 2006;100:2053-9.
57. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127:1064-71.
58. Kolde G, Muche JM, Schulze P, Fischer P, Lichey J. Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology. 2003;206:180-1.
59. Hertl MS, Haendle I, Schuler G, Hertl M. Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol. 2005;152:552-5.
60. Fardet L, Dupuy A, Kerob D, Levy A, Allez M, Begon E, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007;56:624-8.
61. Usmani N, Clayton TH, Everett S, Goodfield MD. Variable response of hidradenitis suppurativa to infliximab in four patients. Clin Exp Dermatol. 2007;32:204-5.
62. Sullivan TP, Welsh E, Kerdel FA, Burdick AE, Kirsner RS. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003;149:1046-9.
63. Thielen AM, Barde C, Saurat JH. Long-term infliximab for severe hidradenitis suppurativa. Br J Dermatol. 2006;155:1105-7.
64. Rosi YL, Lowe L, Kang S. Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatol Treat. 2005;16:58-61.
65. Martínez F, Nos P, Benlloch S, Ponce J. Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis. 2001;7:323-6.
66. Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2003;49 Suppl 5:S275-6.
67. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003;139:1540-2.
68. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol. 2002;97(8):2155-6.
69. Roussomoustakaki M, Dimoulios P, Chatzicostas C, Kritikos HD, Romanos J, Panayiotides JG, et al. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol. 2003;38:1000-4.
70. Shirakawa M, Uramoto K, Harada FA. Treatment of acne conglobata with infliximab. J Am Acad Dermatol. 2006;55:344-6.
71. Olivieri I, Padula A, Ciancio G, Salvarani C, Niccoli L, Cantini F. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis. 2002;61:375-6.
72. Deutschmann A, Mache CJ, Bodo K, Zebedin D, Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics. 2005;116:1231-3.
73. Iqbal M, Kolodney MS. Acne fulminans with synovitis-acne-pustulosis- hyperostosis-osteitis (SAPHO) syndrome treated with infliximab. J Am Acad Dermatol. 2005; 52 Suppl 1:S118-20.
74. Massara A, Cavazzini PL, Trotta F. In SAPHO syndrome anti-TNF-alpha therapy may induce persistent amelioration of osteoarticular complaints, but may exacerbate cutaneous manifestations. Rheumatology (Oxford). 2006;45:730-3.
75. Reguiai Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in pyoderma gangrenosum associated with inflammatory Bowel disease. Am J Clin Dermatol. 2007;8:67-77.
76. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98(8):1821-6.
77. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002;37:1108-10.
78. Rispo A, Scarpa R, Di Girolamo E, Cozzolino A, Lembo G, Atteno M, et al. Infliximab in the treatment of extraintestinal manifestations of Crohn's disease. Scand J Rheumatol. 2005;34:387-91.
79. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int. 2005;25:406-10.
80. Kouklakis G, Moschos J, Leontiadis GI, Kadis S, Mpoumponaris A, Molyvas E, et al. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report. Rom J Gastroenterol. 2005;14:401-3.
81. Krag AA, Gjersoe P. [Treatment with infliximab of peristomal pyoderma gangrenosum in ulcerative colitis]. Ugeskr Laeger. 2005;167:1968-9.
82. Swale VJ, Saha M, Kapur N, Hoffbrand AV, Rustin MH. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol. 2005;30:134-6.
83. Uthman I, El-Sayad J, Sharara A. Successful treatment of recalcitrant pyoderma gangrenosum with infliximab complicated by tuberculosis despite negative screening tests. Clin Exp Dermatol. 2005;30:294.
84. Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol. 2005;153: 689-91.
85. Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol. 2004;29:196-7.
86. Jenne L, Sauter B, Thumann P, Hertl M, Schuler G. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol. 2004;150:380-2.
87. López San Román A, Bermejo F, Aldanondo I, Carrera E, Boixeda D, Muñoz Zato E. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig. 2004;96:420-2; 2-4.
88. Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn's disease. Dig Dis Sci. 2004;49(9):1454-7.
89. Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37:150-4.
90. Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813-6.
91. Zaccagna A, Bertone A, Puiatti P, Picciotto F, Sprujevnik T, Santucci R, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease. Eur J Dermatol. 2003;13:258-60.
92. Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15):1639-46.
93. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558-60.
94. Botros N, Pickover L, Das KM. Image of the Month. Pyoderma gangrenosum caused by ulcerative colitis. Gastroenterology. 2000;118:654-809.
95. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology. 2002;205:278-80.
96. Romero-Gómez M, Sánchez-Muñoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol. 2002;14:907.
97. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg. 2000;135:564-8.
98. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001;137(7):930-3.
99. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol. 2002;37:863-5.
100. De la Morena F, Martín L, Gisbert JP, Fernández Herrera J, Goiriz R. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis. 2007;13:509-10.
101. Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol. 2005;22:262-5.
102. Hubbard VG, Friedmann AC, Goldsmith P. Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol. 2005;152:1059-61.
103. Vanbiervliet G, Anty R, Schneider S, Arab K, Rampal P, Hebuterne X. [Sweet's syndrome and erythema nodosum associated with Crohn's disease treated by infliximab]. Gastroenterol Clin Biol. 2002;26:295-7.
104. Rahier JF, Lion L, Dewit O, Lambert M. Regression of Sweet's syndrome associated with Crohn's disease after anti-Tumour Necrosis Factor therapy. Acta Gastroenterol Belg. 2005;68:376-9.
105. Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin Dev Immunol. 2005; 12:145-9.
106. Matzkies FG, Manger B, Schmitt-Haendle M, Nagel T, Kraetsch HG, Kalden JR, et al. Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis. 2003;62:81-2.
107. Voigtlander C, Luftl M, Schuler G, Hertl M. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol. 2001;137:1571-4.
108. Bonifati C, Trento E, Cordiali Fei P, Muscardin L, Amantea A, Carducci M. Early but not lasting improvement of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease) after infliximab therapy: relationships with variations in cytokine levels in suction blister fluids. Clin Exp Dermatol. 2005;30:662-5.
109. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol. 2005;153:448-9.
110. Pardo J, Mercader P, Mahiques L, Sánchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153:222-3.
111. Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol. 2006;142:1268-70.
112. Hajeer AH, Worthington J, Davies EJ, Hillarby MC, Poulton K, Ollier WE. TNF microsatellite a2, b3 and d2 alleles are associated with systemic lupus erythematosus. Tissue Antigens 1997;49:222-7.
113. al-Janadi M, al-Balla S, al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993;13:58-67.
114. Aringer M, Feierl E, Steiner G, Stummvoll GH, Höfler E, Steiner CW, et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus. 2002;11:102-8.
115. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003;9:176-8.
116. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (Oxford). 2006;45:1317-9.
117. Stratigos AJ, Antoniou C, Stamathioudaki S, Avgerinou G, Tsega A, Katsambas AD. Discoid lupus erythematosus-like eruption induced by infliximab. Clin Exp Dermatol. 2004;29:150-3.
118. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359:579-80.
119. Schneider SW, Staender S, Schluter B, Luger TA, Bonsmann G. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. Arch Dermatol. 2006;142:115-6.
120. Richez C, Dumoulin C, Schaeverbeke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. J Rheumatol. 2005;32:760-1.
121. Pérez-García C, Maymo J, Lisbona Pérez MP, Almirall Bernabe M, Carbonell Abello J. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. Rheumatology (Oxford). 2006;45:114-6.
122. Pataka A, Tzouvelekis A, Bouros D. Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption. Eur J Intern Med. 2006;17:520.
123. Pallotta P, Cianchini G, Ruffelli M, Puddu P. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford. 2006;45:116-7.
124. Nakamura I, Tanno M, Katsumata S, Ito K. A lupus-like butterfly rash following infliximab therapy. Mod Rheumatol. 2005;15:223-4.
125. High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. J Am Acad Dermatol. 2005;52:E5.
126. Elkayam O, Caspi D. Infliximab induced lupus in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:502-3.
127. de Langen-Wouterse JJ, Bijl AM, van Grootheest AC. [Drug-induced systemic lupus erythematosus: reports to The Netherlands Pharmacovigilance Centre Lareb]. Ned Tijdschr Geneeskd. 2007;151:367-70.
128. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005;7:R545-51.
129. Chadha T, Hernández JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum. 2006;55:163-6.
130. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol. 2005;11:47-9.
131. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med. 2002;137:625-6.
132. Hoxha A, Ruffatti A, Grypiotis P, Podswiadek M, Botsios C, Fiocco U, et al. [Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab]. Reumatismo. 2006;58:121-6.
133. García-Planella E, Domenech E, Esteve-Comas M, Bernal I, Cabre E, Boix J, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003;15:351-4.
134. Eriksson C, Engstrand S, Sundqvist KG, Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005;64:403-7.
135. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003;48:1015-23.
136. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192-201.
137. Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. J Rheumatol. 2006;33:24-30.
138. Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin Exp Rheumatol. 2004;22:756-8.
139. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
140. Aringer M, Steiner G, Graninger WB, Hofler E, Steiner CW, Smolen JS. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 2007;56:274-9.
141. Hayat SJ, Uppal SS. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol. 2007;17:174-7.
142. Principi M, Di Leo A, Ingrosso M, Pisani A, Marangi S, Amoruso A, et al. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report. Immunopharmacol Immunotoxicol. 2004;26:243-8.
143. Hayat SJ, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol. 2007;26:973-5.
144. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum. 2004;50:3161-9.
145. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol. 1993;13:321-8.
146. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol. 1997;24:663-5.
147. Sato H, Lagan AL, Alexopoulou C, Vassilakis DA, Ahmad T, Pantelidis P, et al. The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum. 2004;50:558-64.
148. Hasegawa M, Sato S, Nagaoka T, Fujimoto M, Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology. 2003;207:141-7.
149. Alekperov RT, Timchenko AV, Nasonov EL. [Tumor necrosis factor alpha in systemic scleroderma]. Klin Med (Mosk). 2003;81:4-7.
150. Young V, Ho M, Vosper H, Belch JJ, Palmer CN. Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis. Rheumatology (Oxford). 2002;41:869-75.
151. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol. 2003;171:3855-62.
152. Hamaguchi M, Kawahito Y, Ishino H, Yoshida M, Yoshikawa T. A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol. 2007;26:988-90.
153. Menon Y, Cucurull E, Espinoza LR. Pancytopenia in a patient with scleroderma treated with infliximab. Rheumatology (Oxford). 2003;42:1273-4; author reply 4.
154. Christopher-Stine L, Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J Rheumatol. 2003;30:2725-7.
155. Ranganathan P. Infliximab-induced scleredema in a patient with rheumatoid arthritis. J Clin Rheumatol. 2005;11:319-22.
156. Magro CM, Crowson AN, Ferri C. Cytomegalovirus-associated cutaneous vasculopathy and scleroderma sans inclusion body change. Hum Pathol. 2007;38:42-9.
157. Antoniou KM, Mamoulaki M, Malagari K, Kritikos HD, Bouros D, Siafakas NM, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol. 2007;25:23-8.
158. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration. 2005. En prensa.
159. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum. 2006;36:168-72.
160. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999;9:239-46.
161. Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2000;2:216-24.
162. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40:865-74.
163. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995;63:9-16.
164. Roddy E, Courtney PA, Morris A. Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford). 2002;41:1194-5.
165. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumornecrosis-factor-alpha: preliminary observations. Eur Neurol 2003;50:10-5.
166. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol. 2004;52:61-3.
167. Dold S, Justiniano ME, Márquez J, Espinoza LR. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol. 2007;26:1186-8.
168. Korkmaz C, Temiz G, Cetinbas F, Buyukkidan B. Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. Rheumatology (Oxford). 2004;43:937-8.
169. Selva-O'Callaghan A, Martínez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford). 2004;43:1196-7.
170. Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65:1233-6.
171. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, Konttinen YT. Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome. Clin Exp Rheumatol. 2001;19:131-7.
172. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270-6.
173. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol. 2004;22 Suppl 34:S14-6.
174. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-84.
175. Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, et al. Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis. 2002;61:560-1.
176. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725-8.
177. Sfikakis PP. Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002; Suppl 2:51-3.
178. Sarwar H, McGrath H Jr., Espinoza LR. Successful treatment of long-standing neuro-Behçet's disease with infliximab. J Rheumatol. 2005;32:181-3.
179. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF {alpha} blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry. 2005;76:1733-5.
180. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-8.
181. Nakamura S, Ohno S. Anti-tumor necrosis factor alpha antibody in the treatment of Behçet's disease. Int Ophthalmol Clin. 2005;45:179-89.
182. Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, et al. Successful treatment of cervical esophageal perforation in Behçet's disease with drainage operation and infliximab. Am J Gastroenterol. 2003;98:703-4.
183. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001;120:995-9.
184. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis. 2001;60:637.
185. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford). 2001;40:473-4.
186. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002;41:1213-4.
187. Rozenbaum M, Rosner I, Portnoy E. Remission of Behçet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis. 2002;61:283-4.
188. Gulli S, Arrigo C, Bocchino L, Morgante L, Sangari D, Castagna I, et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003;4:19.
189. Saulsbury FT, Mann JA. Treatment with infliximab for a child with Behçet's disease. Arthritis Rheum. 2003;49:599-600.
190. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis. 2004;63:744-5.
191. Connolly M, Armstrong JS, Buckley DA. Infliximab treatment for severe orogenital ulceration in Behçet's disease. Br J Dermatol. 2005;153:1073-5.
192. Yucel AE, Kart-Koseoglu H, Akova YA, Demirhan B, Boyacioglu S. Failure of infliximab treatment and occurrence of erythema nodosum during therapy in two patients with Behçet's disease. Rheumatology (Oxford). 2004;43:394-6.
193. Schmaltz C, Alpdogan O, Muriglan SJ, Kappel BJ, Rotolo JA, Ricchetti ET, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101:2440-5.
194. Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood. 1999;93:2738-47.
195. Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, et al. Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation. 2000;70:272-9.
196. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood. 1998;91:4051-5.
197. Grounds MD, Davies M, Torrisi J, Shavlakadze T, White J, Hodgetts S. Silencing TNFalpha activity by using remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res. 2005;320:509-15.
198. Borsotti C, Franklin AR, Lu SX, Kim TD, Smith OM, Suh D, et al. Absence of donor T cell derived soluble TNF decreases graft-versus-host-disease without impairing graft-versus-tumor activity. Blood. 2007;110:783-6.
199. Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011-6.
200. Hervé P, Racadot E, Wijdenes J, Flesch M, Tiberghien P, Bordigoni P, et al. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody. Bone Marrow Transplant. 1991; Suppl 2:149.
201. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma. 1995;17:169-73.
202. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation. 2002;73:665-7.
203. Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr Opin Oncol. 2000;12:582-7.
204. Jacobsohn DA. Novel therapeutics for the treatment of graft-versus-host disease. Expert Opin Investig Drugs. 2002;11:1271-80.
205. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004;104:649-54.
206. Couriel D HK, Ipolotti C. Infliximab for the treatment of graft-versus-host disease in allogenic transplant recipients: an update. Blood. 2000;46:400a.
207. Ross WA. Treatment of gastrointestinal acute graft-versus-host disease. Curr Treat Options Gastroenterol. 2005;8:249-58.
208. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89:1352-9.
209. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant. 2001;28:47-9.
210. Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma. 2003;44:2095-7.
211. Magalhaes-Silverman M HR, Becker A, Gringrich R. Treatment of steroid refractary acute graft versus host disease with infliximab. Blood 2001;98:5208a.
212. Rodríguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer. 2005.
213. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2004;10:655-68.
214. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003;102:2768-76.
215. Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol. 2005;141:423-5.
216. Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. Australas J Dermatol.2006;47:124-9.
217. Lu R, George SJ, Hsu S. Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J. 2006;12:18.
218. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146:707-9.
219. Al-Shouli S, Abouchala N, Bogusz MJ, Al Tufail M, Thestrup-Pedersen K. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol. 2005;85:534-5.
220. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116:923-4.
221. Meiss F, Helmbold P, Meykadeh N, Gaber G, Marsch W, Fischer M. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol. 2007;21:717-9.
222. Booth A, Harper L, Hammad T, Bacon P, Griffith M, Levy J, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol. 2004;15:717-21.
223. Sangle SR, Hughes GR, D'Cruz DP. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects. Ann Rheum Dis. 2007;66:564-5.
224. Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718-23.
225. Bartolucci P, Ramanoelina J, Cohen P, Mahr A, Godmer P, Le Hello C, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41:1126-32.
226. Lamprecht P, Arbach O, Voswinkel J, Lilienthal T, Nölle B, Heller M, et al. [Induction of remission with infliximab in therapy-refractory Wegener's granulomatosis - Follow-up of six patients]. Dtsch Med Wochenschr. 2002;127:1876-80.
227. Farah R, Lisitsin S, Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci. 2006;28:123-5.
228. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis. 2002;61:559.
229. Hermann J, Reittner P, Scarpatetti M, Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. Ann Rheum Dis 2006;65:691-2.
230. Svozilkova P, Rihova E, Brichova M, Diblik P, Kuthan P, Poch T. [Infliximab in the treatment of Wegener's granulomatosis: case report]. Cesk Slov Oftalmol. 2006;62:280-6.
231. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye. 2005;19:1017-8.
232. Kleinert J, Lorenz M, Kostler W, Horl W, Sunder-Plassmann G, Soleiman A. Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. Wien Klin Wochenschr. 2004;116:334-8.
233. Wilkinson NM, Erendzhinova E, Zeft A, Cabral DA. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford). 2006;45:1047-8.
234. Ozdogu H, Boga C, Bolat F, Ertorer ME. Wegener's granulomatosis with a possible thyroidal involvement. J Natl Med Assoc. 2006;98:956-8.
235. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum. 2001;44:1149-54.
236. Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis. 2004;63 Suppl 2:79-83.
237. Torrente SV, Guerri RC, Pérez-García C, Benito P, Carbonell J. Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-alpha. Intern Med J. 2007;37:280-1.
238. Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol. 2006;25:109-10.
239. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621-30.
240. Brik R, Gepstein V, Shahar E, Goldsher D, Berkovitz D. Tumor necrosis factor blockade in the management of children with orphan diseases. Clin Rheumatol. 2007. En prensa.
241. de Kort SW, van Rossum MA, ten Cate R. Infliximab in a child with therapy-resistant systemic vasculitis. Clin Rheumatol. 2006;25:769-71.
242. Wu K, Throssell D. A new treatment for polyarteritis nodosa. Nephrol Dial Transplant. 2006;21:1710-2.
243. Al-Bishri J, le Riche N, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol. 2005;32:1371-3.
244. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss- Syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002;206:496-501.
245. Mang R, Ruzicka T, Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol. 2004;51:321-2.
246. Uthman IW, Touma Z, Sayyad J, Salman S. Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol. 2005;53:353-4.
247. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. J Rheumatol. 2005;32:759.
248. Thirion L PD, Mejjad O, Courville P, Le Loet X, Joly P. [Cutaneous vasculitis with necrotic ulcers in rheumatoid arthritis: treatment with anti-TNFalpha]. Ann Dermatol Venereol. 2006;133:453-5.
249. van der Bijl AE, Allaart CF, Van Vugt J, Van Duinen S, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607-9.
250. Tanaka F, Kawakami A, Iwanaga N, Tamai M, Izumi Y, Aratake K, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med. 2006;45:313-6.
251. Della Rossa A, Tavoni A, Merlini G, Baldini C, Sebastiani M, Lombardi M, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology (Oxford). 2005;44:1074-5.
252. Jolly M, Curran JJ. Infliximab-responsive uveitis and vasculitis in a patient with Takayasu arteritis. J Clin Rheumatol. 2005;11:213-5.
253. Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum. 2004;50:2296-304.
254. Bonilla Hernán MG CIT, De Miguel Mendieta E, Martín Mola E. Tratamiento con infliximab (anti-TNF alpha) en pacientes con enfermedad de Still del adulto. Experiencia de dos casos. An Med Interna. 2004;21:23-6.
255. O'Connor M J, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila). 2007;46:345-8.
256. Stenbog EV, Windelborg B, Horlyck A, Herlin T. The effect of TNFalpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006;35:318-21.
257. Zulian F, Zanon G, Martini G, Mescoli G, Milanesi O. Efficacy of infliximab in long-lasting refractory Kawasaki disease. Clin Exp Rheumatol. 2006;24:453.
258. Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr. 2006;149:426.
259. Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-7.
260. Daysal S, Akcil G, Goker B, Haznedaroglu S, Ercan N, Ozturk MA. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis. Arthritis Rheum. 2005;53:146-7.
261. Metyas S, Arkfeld DG, Forrester DM, Ehresmann GR. Infliximab treatment of familial mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol. 2004;10:134-7.
262. Ozgocmen S, Ozcakar L, Ardicoglu O, Kocakoc E, Kaya A, Kiris A. Familial mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol. 2006;25:83-7.
263. Yuksel S, Yalcinkaya F, Acar B, Ozcakar ZB, Ozturk B, Ekim M. Clinical improvement with infliximab in a child with amyloidosis secondary to familial mediterranean fever. Rheumatology (Oxford). 2006;45:1307-8.
264. Bender NK, Heilig CE, Droll B, Wohlgemuth J, Armbruster FP, Heilig B. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. Rheumatol Int. 2007;27:269-74.
265. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63:508-16.
266. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
267. Keystone E, Haraoui B. Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am. 2004;30:349-64.
268. http://www.emea.europa.eu/humandocs/Humans/EPAR/humira/humira.htm.
269. Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH. Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds. 2006;5:8.
270. Heffernan MP, Anadkat MJ, Smith DI. Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol. 2007;143:306-8.
271. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis. 2007;66:565-6.
272. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye. 2007;21:824-5.
273. Moul DK, Korman NJ. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab. Arch Dermatol. 2006;142:1110-2.
274. Scheinfeld N. Treatment of coincident seronegative arthritis and hidradentis supprativa with adalimumab. J Am Acad Dermatol. 2006;55:163-4.
275. Thirion L, Picard D, Mejjad O, Courville P, Le Loet X, Joly P. [Cutaneous vasculitis with necrotic ulcers in rheumatoid arthritis: treatment with anti-TNFalpha]. Ann Dermatol Venereol. 2006;133:453-5.
276. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007;26:1353-5.
277. Tato F, Rieger J, Hoffmann U. Refractory Takayasu's arteritis successfully treated with the human, monoclonal antitumor necrosis factor antibody adalimumab. Int Angiol. 2005;24:304-7.
278. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005;53:917.
279. Heffernan MP, Smith DI. Adalimumab for treatment of cutaneous sarcoidosis. Arch Dermatol. 2006;142:17-9.
280. Callejas-Rubio JL, Ortego-Centeno N, López-Pérez L, Benticuaga MN. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol. 2006;25:596-7.
281. Fisher GH, Geronemus RG. Treatment of multiple familial trichoepitheliomas with a combination of aspirin and a neutralizing antibody to tumor necrosis factor alpha: A case report and hypothesis of mechanism. Arch Dermatol. 2006;142:782-3.
282. Shannon SE, Schumacher HR, Self S, Brown AN. Multicentric reticulohistiocytosis responding to tumor necrosis factor-alpha inhibition in a renal transplant patient. J Rheumatol. 2005;32:565-7.
283. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol. 2005;53:541-3.